The Role of [18F]F-Choline PET/CT in the Initial Management and Outcome Prediction of Prostate Cancer: A Real-World Experience from a Multidisciplinary Approach

被引:8
作者
Urso, Luca [1 ,2 ]
Rocca, Giovanni Christian [3 ]
Borgia, Francesca [1 ,2 ]
Lancia, Federica [4 ]
Malorgio, Antonio [5 ]
Gagliano, Mauro [6 ]
Zanetto, Mauro [1 ]
Uccelli, Licia [1 ,2 ]
Cittanti, Corrado [1 ,2 ]
Ippolito, Carmelo [4 ]
Evangelista, Laura [7 ]
Bartolomei, Mirco [2 ]
机构
[1] Univ Ferrara, Dept Translat Med, Via Aldo Moro 8, I-44124 Ferrara, Italy
[2] Univ Hosp Ferrara, Oncol Med & Specialist Dept, Nucl Med Unit, I-44124 Ferrara, Italy
[3] Univ Hosp Ferrara, Surg Dept, Urol Unit, I-44124 Ferrara, Italy
[4] Univ Hosp Ferrara, Oncol Med & Specialists Dept, Oncol Unit, I-44124 Ferrara, Italy
[5] Univ Hosp Ferrara, Radiotherapy Unit, I-44124 Ferrara, Italy
[6] Univ Hosp Ferrara, Hosp Radiol, I-44124 Ferrara, Italy
[7] Univ Padua, Dept Med DIMED, I-35128 Padua, Italy
关键词
F-18]F-choline PET/CT; prostate cancer; conventional imaging; outcome; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; GA-68-PSMA-11; PET/CT; COMPUTED-TOMOGRAPHY; BONE METASTASES; CHOLINE-PET/CT; HSPC PATIENTS; HIGH-RISK; MRI; INTERMEDIATE; DIAGNOSIS;
D O I
10.3390/biomedicines10102463
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Initial staging of prostate cancer (PCa) is usually performed with conventional imaging (CI), involving computed tomography (CT) and bone scanning (BS). The aim of this study was to analyze the role of [F-18]F-choline positron emission tomography (PET)/CT in the initial management and outcome prediction of PCa patients by analyzing data from a multidisciplinary approach. We retrospectively analyzed 82 patients who were discussed by the uro-oncology board of the University Hospital of Ferrara for primary staging newly diagnosed PCa (median age 72 (56-86) years; median baseline prostate specific antigen (PSA) equal to 8.73 ng/mL). Patients were divided into three groups based on the imaging performed: group A = only CI; group B = CI + [F-18]F-choline PET/CT; group C = only [F-18]F-choline PET/CT. All data on imaging findings, therapy decisions and patient outcomes were retrieved from hospital information systems. Moreover, we performed a sub-analysis of semiquantitative parameters extracted from [F-18]F-choline PET/CT to search any correlation with patient outcomes. The number of patients included in each group was 35, 35 and 12, respectively. Patients with higher values of initial PSA were subjected to CI + PET/CT (p = 0.005). Moreover, the use of [F-18]F-choline PET/CT was more frequent in patients with higher Gleason score (GS) or ISUP grade (p = 0.013). The type of treatment performed (surgery n = 33; radiation therapy n = 22; surveillance n = 6; multimodality therapy n = 6; systemic therapy n = 13; not available n = 2) did not show any relationship with the modality adopted to stage the disease. [F-18]F-choline PET/CT induced a change of planned therapy in 5/35 patients in group B (14.3%). Moreover, patients investigated with [F-18]F-choline PET/CT alone demonstrated longer biochemical recurrence (BCR)-free survival (30.8 months) in comparison to patients of groups A and B (15.5 and 23.5 months, respectively, p = 0.006), probably due to a more accurate selection of primary treatment. Finally, total lesion choline kinase activity (TLCKA) of the primary lesion, calculated by multiplying metabolic tumor volume and mean standardized uptake value (SUVmean), was able to more effectively discriminate patients who had recurrence after therapy compared to those without (p = 0.03). In our real-world experience [F-18]F-choline PET/CT as a tool for the initial management of PCa had a relevant impact in terms of therapy selection and was associated with longer BCR-free survival. Moreover, TLCKA of the primary lesion looks a promising parameter for predicting recurrence after curative therapy.
引用
收藏
页数:12
相关论文
共 50 条
[41]   The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis [J].
Wang, Rang ;
Shen, Guohua ;
Huang, Mingxing ;
Tian, Rong .
FRONTIERS IN ONCOLOGY, 2021, 11
[42]   Diagnostic performance of 18F-choline PET-CT in prostate cancer [J].
P. Samper Ots ;
A. Luis Cardo ;
C. Vallejo Ocaña ;
M. A. Cabeza Rodríguez ;
L. A. Glaria Enríquez ;
M. L. Couselo Paniagua ;
J. Olivera Vegas .
Clinical and Translational Oncology, 2019, 21 :766-773
[43]   Diagnostic performance of 18F-choline PET-CT in prostate cancer [J].
Samper Ots, P. ;
Luis Cardo, A. ;
Vallejo Ocana, C. ;
Cabeza Rodriguez, M. A. ;
Glaria Enriquez, L. A. ;
Couselo Paniagua, M. L. ;
Olivera Vegas, J. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (06) :766-773
[44]   18F-choline PET/MRI on initial staging of prostate cancer. Impact on therapy approach [J].
Garcia, J. R. ;
Compte, A. ;
Galan, C. ;
Cozar, M. ;
Buxeda, M. ;
Mourelo, S. ;
Pineiro, T. ;
Soler, M. ;
Valls, E. ;
Bassa, P. ;
Santabarbara, J. M. .
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2021, 40 (02) :72-81
[45]   The Added Value of [18F]Choline PET/CT in Low-Risk Prostate Cancer Staging: A Case Report [J].
Piras, Antonio ;
Laudicella, Riccardo ;
Boldrini, Luca ;
D'Aviero, Andrea ;
Sanfratello, Antonella ;
La Rocca, Antonino ;
Scurria, Salvatore ;
Salamone, Giuseppe ;
Alongi, Pierpaolo ;
Angileri, Tommaso ;
Daidone, Antonino .
LIFE-BASEL, 2022, 12 (11)
[46]   Influence of hormonal therapy in prostate cancer patients undergoing [18F] fluoromethyl choline PET/CT: a retrospective study [J].
Palumbo, Barbara ;
Sivolella, Silvio ;
Palumbo, Isabella ;
Buresta, Tommaso ;
Radicchia, Valentina ;
Fravolini, Mario L. ;
Ferretti, Francesca ;
Bellavita, Rita ;
Mearini, Luigi ;
Scialpi, Michele ;
Aristei, Cynthia ;
Pelliccia, Gianfranco .
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 60 (04) :397-403
[47]   A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer [J].
Zanoni, Lucia ;
Bossert, Irene ;
Matti, Antonella ;
Schiavina, Riccardo ;
Pultrone, Cristian ;
Fanti, Stefano ;
Nanni, Cristina .
FUTURE ONCOLOGY, 2018, 14 (11) :1101-1115
[48]   Current Evaluation of the Clinical Utility of Fluoromethylcholine-(18F) PET/CT in Prostate Cancer [J].
Talbot, Jean-Noeel ;
Chevalme, Yanna-Marina .
BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY, 2008, 51 :71-75
[49]   Role of [18F]FAPI-04 in staging and therapeutic management of intrahepatic cholangiocarcinoma: prospective comparison with [18F]FDG PET/CT [J].
Liang, Jiucen ;
Jiang, Shuqin ;
Song, Jingjing ;
Chen, Danyang ;
Weng, Shaojuan ;
Li, Shuyi ;
Peng, Hao ;
Liu, Zhidong ;
Zhang, Jing ;
Chen, Yuanlin ;
Rao, Songquan ;
Chen, Haipeng ;
Zhang, Rusen ;
Liu, Hao ;
Zhang, Linqi .
EJNMMI RESEARCH, 2024, 14 (01)
[50]   [18F]Fluciclovine PET/CT Improves the Clinical Management of Early Recurrence Prostate Cancer Patients [J].
Nappi, Anna Giulia ;
Ferrari, Cristina ;
Mammucci, Paolo ;
Rubini, Dino ;
Lavelli, Valentina ;
Sardaro, Angela ;
Pisani, Antonio Rosario ;
Rubini, Giuseppe .
CANCERS, 2022, 14 (06)